- Home
- RGC vs TCRX Comparison
RGC vs TCRX Comparison
Compare RGC & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGC
- TCRX
- Stock Information
- Founded
- RGC 2014
- TCRX 2018
- Country
- RGC Hong Kong
- TCRX United States
- Employees
- RGC N/A
- TCRX N/A
- Industry
- RGC Medicinal Chemicals and Botanical Products
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- RGC Health Care
- TCRX Health Care
- Exchange
- RGC Nasdaq
- TCRX Nasdaq
- Market Cap
- RGC 105.3M
- TCRX 115.8M
- IPO Year
- RGC 2021
- TCRX 2021
- Fundamental
- Price
- RGC $4.50
- TCRX $2.17
- Analyst Decision
- RGC
- TCRX Strong Buy
- Analyst Count
- RGC 0
- TCRX 5
- Target Price
- RGC N/A
- TCRX $11.40
- AVG Volume (30 Days)
- RGC 32.6K
- TCRX 382.5K
- Earning Date
- RGC 10-25-2024
- TCRX 03-05-2025
- Dividend Yield
- RGC N/A
- TCRX N/A
- EPS Growth
- RGC N/A
- TCRX N/A
- EPS
- RGC N/A
- TCRX N/A
- Revenue
- RGC N/A
- TCRX $9,362,000.00
- Revenue This Year
- RGC N/A
- TCRX N/A
- Revenue Next Year
- RGC N/A
- TCRX $5.14
- P/E Ratio
- RGC N/A
- TCRX N/A
- Revenue Growth
- RGC N/A
- TCRX N/A
- 52 Week Low
- RGC $3.03
- TCRX $1.99
- 52 Week High
- RGC $32.44
- TCRX $9.69
- Technical
- Relative Strength Index (RSI)
- RGC 57.18
- TCRX 37.12
- Support Level
- RGC $3.53
- TCRX $2.02
- Resistance Level
- RGC $3.86
- TCRX $2.17
- Average True Range (ATR)
- RGC 0.21
- TCRX 0.16
- MACD
- RGC 0.10
- TCRX 0.02
- Stochastic Oscillator
- RGC 91.55
- TCRX 26.47
About RGC Regencell Bioscience Holdings Limited
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.